Chronic ulcers cause persistent pain and impaired healing, often showing resistance to standard therapies. Topical sevoflurane has emerged as a potential agent for both pain relief and wound healing; however, current evidence remains limited. This review assesses the safety and efficacy of topical sevoflurane in managing painful chronic ulcers and promoting a reduction in ulcer size.
Objective
To assess the safety and efficacy of topical sevoflurane as a promising drug compared with standard care.
Methods
We searched PubMed, Web of Science, Cochrane Library, and Scopus up to March 2025 for studies on topical sevoflurane in chronic ulcers. Meta-analysis was based on the Cochrane Handbook for Systematic Reviews of Intervention.
Results
Our meta-analysis showed that three studies (n = 127) demonstrated a significant reduction in pain with topical sevoflurane treatment, with a pooled Standardized Mean Difference (SMD) of −1.88 (95% CI: −2.31 to −1.44, P < .0001), and low heterogeneity (I² = 18.9%). Ulcer size reduction was also statistically significant in two studies (n = 79), with a pooled mean difference of −4.77 cm² (95% CI: −7.30 to −2.23, P = .0002), and moderate heterogeneity (I² = 30.0%). Effects were more pronounced at earlier assessment time points.
Conclusion
Topical sevoflurane shows promise for pain management in chronic ulcers, with potential benefits for healing and reducing opioid use. However, stronger evidence from high-quality studies is needed to support a definitive recommendation.
MartinengoLOlssonMBajpaiR, et al.Prevalence of chronic wounds in the general population: systematic review and meta-analysis of observational studies. Ann Epidemiol. 2019;29:8–15. doi:10.1016/j.annepidem.2018.10.005
2.
ZhuXOlssonMMBajpaiRJärbrinkKTangWECarJ. Health-related quality of life and chronic wound characteristics among patients with chronic wounds treated in primary care: a cross-sectional study in Singapore. Int Wound J. 2022;19(5):1121–1132. doi:10.1111/iwj.13708
3.
IvoryJDFinnDPVellingaA, et al.Topical interventions for the management of pain in chronic wounds: a protocol for a systematic review. HRB Open Res. 2022;5:58. doi:10.12688/hrbopenres.13560.1
4.
PricePFoghKGlynnCKrasnerDLOsterbrinkJSibbaldRG. Managing painful chronic wounds: the Wound Pain Management Model. Int Wound J. 2007;4(Suppl 1):4–15. doi:10.1111/j.1742-481X.2007.00311.x
5.
PricePEFagervik-MortonHMudgeEJ, et al.Dressing-related pain in patients with chronic wounds: an international patient perspective. Int Wound J. 2008;5(2):159–171. doi:10.1111/j.1742-481X.2008.00471.x
6.
MeaumeSTéotLLazarethIMartiniJBohbotS. The importance of pain reduction through dressing selection in routine wound management: the MAPP study. J Wound Care. 2004;13(10):409–413. doi:10.12968/jowc.2004.13.10.27268
7.
SzorJ. Description of pressure ulcer pain at rest and at dressing change. J WOCN. 1999;26(3):115–120. doi:10.1016/S1071-5754(99)90028-1
8.
EvansARPinzurMS. Health-related quality of life of patients with diabetes and foot ulcers. Foot Ankle Int. 2005;26(1):32–37. doi:10.1177/107110070502600106
9.
Domingo-TriadóVLópez AlarcónMDVillegas EstévezF, et al.Tratamiento del dolor irruptivo con fentanilo sublingual en pacientes con úlceras cutáneas crónicas. Rev Esp Anestesiol Reanim. 2014;61(8):429–433. doi:10.1016/j.redar.2014.01.005
10.
BenyaminRTrescotAMDattaS, et al.Opioid complications and side effects. Pain Physician. 2008;11(2 Suppl):S105–S120.
11.
PurcellABuckleyTKingJMoyleWMarshallAP. Topical analgesic and local anesthetic agents for pain associated with chronic leg ulcers: a systematic review. Adv Skin Wound Care. 2020;33(5):240–251. doi:10.1097/01.ASW.0000658572.14692.fb
12.
HolstRGKristoffersonA. Lidocaine-prilocaine cream (EMLA Cream) as a topical anaesthetic for the cleansing of leg ulcers. The effect of length of application time. Eur J Dermatol EJD. 1998;8(4):245–247.
13.
BriggsMNelsonEAMartyn-St JamesM. Topical agents or dressings for pain in venous leg ulcers. Cochrane Wounds Group, ed. Cochrane Database Syst Rev. 2012. Published online November 14, 2012. doi:10.1002/14651858.CD001177.pub3
14.
AbbVie Inc. U.S. Prescribing Information: Ultane® (Sevoflurane) Volatile Liquid for Inhalation. AbbVie Inc.; 2017.
15.
Gerónimo-PardoMMartínez-MonsalveAMartínez-SerranoM. Analgesic effect of topical sevoflurane on venous leg ulcer with intractable pain. Phlebologie. 2011;40(02):95–97. doi:10.1055/s-0037-1621757
16.
Losa-PalaciosSAchaerandio-de NovaARestrepo-PérezMGerónimo-PardoM. Uncooperative patient with an infected elbow osteosynthesis: alternative management with topical sevoflurane. Wounds Compend Clin Res Pract. 2019;31(10):E68–E72.
17.
Dámaso Fernández-GinésFCortiñas-SáenzMNavajas-Gómez de ArandaAYoldi BocanegraRSierra-GarcíaF. Reply: to chronic venous ulcer treatment with topical sevoflurane by Imbernón et al. Int Wound J. 2017;14(3):591. doi:10.1111/iwj.12709
18.
Fernández-GinésFDCortiñas-SáenzMNavajas-Gómez De ArandaA, et al.Palliative analgesia with topical sevoflurane in cancer-related skin ulcers: a case report. Eur J Hosp Pharm. 2019;26(4):229–232. doi:10.1136/ejhpharm-2017-001421
19.
Rueda-MartínezJLGerónimo-PardoMMartínez-MonsalveAMartínez-SerranoM. Topical sevoflurane and healing of a post-operative surgical site superinfected by multi-drug-resistant Pseudomonas aeruginosa and susceptible Staphylococcus aureus in an immunocompromised patient. Surg Infect. 2014;15(6):843–846. doi:10.1089/sur.2013.079
20.
Gerónimo PardoMCortiñas SáenzM. Eficacia analgésica del sevoflurano tópico en heridas. Rev Soc Esp Dolor. 2017. doi:10.20986/resed.2017.3617/2017
21.
CumpstonMLiTPageMJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Editorial Unit, ed. Cochrane Database Syst Rev. 2019. Published online October 3, 2019. doi:10.1002/14651858.ED000142
22.
OuzzaniMHammadyHFedorowiczZElmagarmidA. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016;5(1):210. doi:10.1186/s13643-016-0384-4
23.
SterneJACSavovićJPageMJ, et al. Rob 2: a revised tool for assessing risk of bias in randomised trials. Br Med J.2019:l4898. Published online August 28, 2019. doi:10.1136/bmj.l4898
24.
WellsGSheaBO’ConnellDPetersonJ. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. Ottawa Hospital Research Institute; Ottawa, ON; 2000. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
HigginsJPTThomasJChandlerJ, et al. (eds). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (Updated August 2024). Cochrane; 2024.
27.
EggerMSmithGDSchneiderMMinderC. Bias in meta-analysis detected by a simple, graphical test. Br Med J.1997;315(7109):629–634. doi:10.1136/bmj.315.7109.629
28.
GolledgeJParraSAldonsPM, et al.A randomised, double-blind, placebo-controlled study to determine the analgesic efficacy, safety and tolerability of VPX638 administered topically to painful wounds. Wound Repair Regen. 2025;33(1):e70008. doi:10.1111/wrr.70008
29.
Gómez SánchezMTHernándezBTFernández-GinésFDCortiñas-SáenzM. [Translated article] Chronic outpatient treatment with topical sevoflurane in patients with vascular ulcers. Farm Hosp. 2024;48(1):T34–T37. doi:10.1016/j.farma.2023.10.001
30.
Cortiñas-SáenzMDámaso Fernández-GinésFSelva-SevillaCGerónimo-PardoM. At-home topical sevoflurane added to the conventional analgesic treatment for painful leg ulcers greatly improved the analgesic effectiveness and reduced opioid consumption in a single-center retrospective comparative study with one-year follow-up. Int J Low Extrem Wounds. 2022:15347346221111418. Published online July 14, 2022. doi:10.1177/15347346221111418
31.
Selva-SevillaCFernández-GinésFDCortiñas-SáenzMGerónimo-PardoM. Cost-effectiveness analysis of domiciliary topical sevoflurane for painful leg ulcers. Zúniga-González CA, ed. PLoS One. 2021;16(9):e0257494. doi:10.1371/journal.pone.0257494
32.
Fernández-GinésFDCortiñas-SáenzMAgudo-PonceD, et al.Pain reduction of topical sevoflurane vs intravenous opioids in pressure ulcers. Int Wound J. 2020;17(1):83–90. doi:10.1111/iwj.13235
33.
Martínez-MonsalveASelva-SevillaCGerónimo-PardoM. Analgesic effectiveness of topical sevoflurane to perform sharp debridement of painful wounds. J Vasc Surg. 2019;69(5):1532–1537. doi:10.1016/j.jvs.2018.08.175
34.
Dámaso Fernández-GinésFCortiñas-SáenzMMateo-CarrascoH, et al.Efficacy and safety of topical sevoflurane in the treatment of chronic skin ulcers. Am J Health Syst Pharm. 2017;74(9):e176–e182. doi:10.2146/ajhp151008
35.
Imbernon-MoyaAOrtiz-de FrutosFJSanjuan-AlvarezMPortero-SanchezIMerinero-PalomaresRAlcazarV. Healing of chronic venous ulcer with topical sevoflurane. Int Wound J. 2017;14(6):1323–1326. doi:10.1111/iwj.12806
36.
HjermstadMJFayersPMHaugenDF, et al.Studies comparing numerical rating scales, verbal rating scales, and visual analogue scales for assessment of pain intensity in adults: A systematic literature review. J Pain Symptom Manage. 2011;41(6):1073–1093. doi:10.1016/j.jpainsymman.2010.08.016
37.
BielewiczJDanilukBKamieniakP. VAS And NRS, same or different? Are visual analog scale values and numerical rating scale equally viable tools for assessing patients after microdiscectomy?Taiar R, ed. Pain Res Manag. 2022;2022:1–6. doi:10.1155/2022/5337483
38.
Lafuente-UrrezRFGilaberteY. Sevoflurano, ¿una alternativa en el tratamiento de las úlceras vasculares?Actas Dermo-Sifiliográficas. 2014;105(2):202–203. doi:10.1016/j.ad.2013.02.010
39.
ImbernónABlázquezCPueblaA, et al.Chronic venous ulcer treatment with topical sevoflurane. Int Wound J. 2016;13(5):1060–1062. doi:10.1111/iwj.12474
40.
MatuteERivera-ArconadaILópez-GarcíaJA. Effects of propofol and sevoflurane on the excitability of rat spinal motoneurones and nociceptive reflexes in vitro. Br J Anaesth. 2004;93(3):422–427. doi:10.1093/bja/aeh217
41.
SkouteriIStaikouCSarantopoulosCSiafakaIFassoulakiA. Local application of halothane, isoflurane or sevoflurane increases the response to an electrical stimulus in humans. Acta Anaesthesiol Belg. 2007;58(3):169–175.
42.
LeeWTNakamuraMChoJHJangIS. Sevoflurane excites nociceptive sensory neurons by inhibiting K+ conductances in rats. Neurosci Lett. 2021;756:135951. doi:10.1016/j.neulet.2021.135951
43.
KantorJMargolisDJ. A multicentre study of percentage change in venous leg ulcer area as a prognostic index of healing at 24 weeks: VENOUS LEG ULCER AREA and PROGNOSIS. Br J Dermatol. 2000;142(5):960–964. doi:10.1046/j.1365-2133.2000.03478.x
44.
ThorlaciusKBodelssonM. Sevoflurane promotes endothelium-dependent smooth muscle relaxation in isolated human omental arteries and veins. Anesth Analg. 2004:423–428. Published online August 2004. doi:10.1213/01.ANE.0000121771.78755.F4
45.
ÇelikEArslankozSKoyuncuPÖğüşEPolatRDönmezA. From anesthesia to healing: the potential of topical sevoflurane in enhancing wound repair. Eurasian J Anesthesiol Intensive Care. 2025;2(1):1–6. doi:10.51271/EAJAIC-0021
46.
WangZWuCZhangMDongANiuRZhangJ. Sevoflurane promotes the proliferation of HUVECs by activating VEGF signaling. Exp Ther Med. 2019. Published online December 12, 2019. doi:10.3892/etm.2019.8319
BechertKAbrahamSE. Pain management and wound care. J Am Coll Certif Wound Spec. 2009;1(2):65–71. doi:10.1016/j.jcws.2008.12.001
49.
LeeKLeeSKimJ. Wound pain management: the present and the future. J Wound Manag Res. 2024;20(3):199–211. doi:10.22467/jwmr.2024.03153
50.
Imbernón-MoyaAOrtiz-de FrutosFJSanjuan-AlvarezMPortero-SanchezIMerinero-PalomaresRAlcazarV. Topical sevoflurane for chronic venous ulcers infected by multi-drug-resistant organisms. Int Wound J. 2017;14(6):1388–1390. doi:10.1111/iwj.12794
RulloLMorosiniCLacorteA, et al.Opioid system and related ligands: from the past to future perspectives. J Anesth Analg Crit Care. 2024;4(1):70. doi:10.1186/s44158-024-00201-2
53.
HoffmannSMHartmannALNieratschkerPMusslerMBSchemppCM. Acute systemic toxicity caused by topical application of EMLA cream on a leg ulcer: case report and review of literature. Dermatol Ther. 2024;14(4):1057–1062. doi:10.1007/s13555-024-01139-7
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
